Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Venrock Healthcare Capital Par Acquires 15,000 Shares of Company Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par acquired 15,000 shares of the company’s stock in a transaction dated Wednesday, October 28th. The stock was purchased at an average cost of $25.45 per share, with a total value of $381,750.00. Following the completion of the purchase, the insider directly owned 6,840,233 shares of the company’s stock, valued at approximately $174,083,929.85. This represents a 0.22% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, October 30th, Venrock Healthcare Capital Par acquired 9,004 shares of Lycia Therapeutics stock. The stock was acquired at an average cost of $26.28 per share, with a total value of $236,625.12.
• On Thursday, October 29th, Venrock Healthcare Capital Par bought 1,000 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $26.33 per share, for a total transaction of $26,330.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par purchased 39,796 shares of Lycia Therapeutics stock. The stock was bought at an average cost of $26.62 per share, for a total transaction of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par purchased 1,952,705 shares of Lycia Therapeutics stock. The shares were purchased at an average price of $18.04 per share, with a total value of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock. The shares were purchased at an average price of $25.91 per share, with a total value of $1,371,649.49.

Lycia Therapeutics Trading Down 4.8%

Shares of LYCA traded down $1.33 during mid-day trading on Friday, reaching $26.40. The company’s stock had a trading volume of 202,428 shares, compared to its average volume of 857,210. Lycia Therapeutics, Inc. has a 12-month low of $22.19 and a 12-month high of $36.49.

About Lycia Therapeutics

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.